


07 Aprile 2026

IRST IRCCS
"Dino Amadori"
Meldola (FC)

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

With Patronage of



LUNG CANCER: WHERE WE ARE?

Fourth Edition

SCIENTIFIC CHAIRS:

Angelo Delmonte
Nicola Normanno
Elisabetta Parisi
Lucio Crinò

PROMOTED BY

IRST IRCCS "Dino Amadori"
MELDOLA
UFFICIO FORMAZIONE:
ufficio.formazione@irst.emr.it

Provider n. 2773 e
Segreteria Organizzativa



SCIENTIFIC RATIONALE

Lung cancer is the first cause of death for tumors worldwide.

However several improvements have been obtained mainly due to the increased biologic knowledge.

In fact today with the term lung cancer we consider a group of several diseases, distinguished according to histology and molecular features.

These aspects are fundamental in order to define the most active therapeutic strategies. This landscape is rapidly evolving and every year new data are available.

So far it is particularly important to have the possibility to discuss the new data together with outstanding experts in order to improve the knowledge for a better cure for patients.

SCIENTIFIC PROGRAM

08.30 Registration

**09.00 Greetings from Directors
and from Scientific Chairs**

**Early stage and locally
advanced non small-cell
lung cancer**

Chairs

**E. Parisi Meldola (FC)
S. Tamberi Ravenna
A. Romeo Rimini**

**9.15 Screening update in Europe in
lung cancer**
U. Pastorino Milano

**9.30 Pre-operative staging for
NSCLC**
V. Poletti Forli

**09.45 Surgery after neoadjuvant
chemo-immunotherapy: more
difficulties and how to overtake
them**
D. Argnani Ravenna

**10.00 Neoadjuvant approaches in
early stages, non oncogene
addicted NSCLC: how to choose
between pre and peri operative
approach**
A. Ardizzoni Bologna

**10.15 Adjuvant approaches in early
stages: an evolving landscape**
F. Passiglia Orbassano

**10.30 Stage IIIB unresectable,
locally advanced NSCLC**
M. Tiseo Parma

**10.45 Radiotherapy as an
alternative to surgery in early
stage NSCLC**
A. Filippi Milano

11.00 Discussion

11.15 Coffee Break

**Oncogene addicted,
advanced diseases (Session
also accredited for Nurses
and Biologists)**

Chairs

**P. Ulivi Meldola (FC)
L. Crinò Meldola (FC)**

**11.30 Sex and gender in lung
cancer: which role?**
R. Berardi Ancona

**11.45 Liquid biopsy in lung cancer:
where are we?**
U. Malapelle Napoli

**12.00 EGFR mutants: different
therapies for different tumors**
A. Passaro Milano

**12.15 KRAS oncogene addicted
tumors**
D. Cortinovia Monza

**12.30 Rare oncogene addicted
tumors (ALK, ROS1, BRAF, RET, MET,
NTRK, HER2)**
K. Andrikou Meldola (FC)

SCIENTIFIC PROGRAM

12.45 Antibody Conjugates in lung cancer
F. Cappuzzo Roma

13.00 Discussion

13.15 Light Lunch

Advanced non-oncogene driven diseases

Chairs

C. Bennati Ravenna
L. Ridolfi Meldola (FC)

14.15 Artificial Intelligence in lung cancer
L. Mazzeo Milano

14.30 Immunotherapy in NSCLC: how to use it
R. Chiari Pesaro

14.45 Mechanism of Resistance to immunocheckpoint inhibitors
G. Lamberti Bologna

15.00 New ways in immunotherapy
S. Pilotto Verona

15.15 Phase 1 clinical trial: advantages and limits in NSCLC
M. Filetti Roma

15.30 Discussion

Rare Thoracic Cancers (Session also accredited for Nurses and Biologists)

Chairs

D. Tassinari Rimini
A. Delmonte Meldola (FC)

15.45 Tumors of the Thymus: future perspectives
T. M. De Pas Bergamo

16.00 Small Cell Lung Cancer: state of the art for local and extended disease
A. Verlicchi Meldola (FC)

16.15 Small Cell Lung Cancer: new therapeutic options
F. Bertolini Modena

16.30 Pleural mesothelioma: a new landscape?
L. Calabrò Ferrara

16.45 Discussion

17.00 Conclusions

Con il contributo educativo non
condizionante di

AstraZeneca 



Boehringer
Ingelheim

 Bristol Myers Squibb®

 Daiichi-Sankyo

AstraZeneca 

Johnson & Johnson

MERCK

 MSD

Pharma
Mar 

 Pfizer
Oncology

REGENERON
SCIENCE TO MEDICINE®

Roche

Takeda

ISCRIZIONE

L'iscrizione si effettua
scaricando

L'APP PROEVENTI



**1. Scarica l'app PROEVENTI
sul tuo smartphone**

**2. Crea il tuo account con le
proprie credenziali o fai il
login se già iscritto**

3. Inserire il pin dell'evento:

per Medico Chirurgo

LUNG26

per Altre Discipline

CANCER26

**4. Ora sei sulla pagina
dell'evento,**

**clicca su ISCRIZIONE in alto
a sinistra**

5. Clicca su ISCRIVITI QUI

PROMOSSO DA

IRST IRCCS MELDOLA "Dino Amadori"

UFFICIO FORMAZIONE:

ufficio.formazione@irst.emr.it

CREDITI ECM

Evento n° 2773 - 473506

Obiettivo n. 3

N. 7 crediti ECM per:

- Medici (Malattie dell'apparato respiratorio; Oncologia; Radioterapia; Chirurgia Generale; Anatomia Patologica; Medicina Nucleare; Radiodiagnostica)
- Farmacisti

Evento n° 2773 - 473510

Obiettivo n. 3

N. 3 crediti ECM per:

- Biologi
- Infermieri

SEDE CONGRESSUALE

**Via Piero Maroncelli, 40,
47014 Meldola (FC)**

**SEGRETERIA
ORGANIZZATIVA E
PROVIDER**



info@proeventi.it

www.proeventi.it